&nbsp;

Feb 2025

Drug

degarelix

Other Name(s): Firmagon®

Quick Link(s):

Feb 2025

Drug

dacarbazine

Quick Link(s):

Jun 2025

Drug

lapatinib

Other Name(s): Tykerb®

Quick Link(s):

Sep 2025

Drug

lomustine

Other Name(s): CeeNU®

Quick Link(s):

Aug 2024

Drug

daBRAFenib

Other Name(s): Tafinlar®

Quick Link(s):

Jun 2025

Drug

lanreotide

Other Name(s): Somatuline® Autogel®

Quick Link(s):

Jun 2024

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DCRB

Cancer Type:

Sarcoma,

Soft Tissue,

Skin,

Melanoma

Intent: Palliative

Drugs Used:

dacarbazine

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DEXA(PO)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

dexamethasone

Quick Link(s):

Regimen Monograph

Sep 2019

Regimen

DOCE(W)PRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

DOCEtaxel,

prednisone

Quick Link(s):

Regimen Monograph

May 2024

Regimen

LETR

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

letrozole

Drugs Used:

letrozole